The independent source for health policy research, polling, and news.
1,161 - 1,180 of 4,438 Results
Aduhelm, the Alzheimer's drug made by Biogen, which costs $56,000 a year, is driving up the overall price that all older Americans pay for Medicare outpatient care. The 14.5% increase is the third-largest percentage increase since 2007.
The drug maker said its recent controversially-approved drug Aduhelm also lowers levels of a second protein that accumulates in the brains of people suffering Alzheimer's. A separate Alzheimer's drug from Cortexyme is moving forward in trials under a new regime.
Genentech's semorinemab drug confused researchers by showing a slower rate of cognitive decline for some patients, but it didn't improve patients' functions compared with a placebo. Separately, reports say Google is aiming to use artificial intelligence to boost breast cancer screening.
In other reports on Medicare, the savings in drug price legislation won't be felt immediately, but rather over a decade or more; advice on the Medicare gap; and appealing income-related charges.
Some insurers pocketed ‘eye-popping’ overpayments, billing records show.
They want changes on the time period of drug exclusivity and the tax treatment of rare disease drugs -- and are shelling out record lobbying dollars to influence the bill. Also, news on the Biden administration efforts to get covid vaccine to war-ravaged countries.
Pfizer and BioNTech applied to the Food and Drug Administration to allow an additional covid vaccine dose to any American 18 and older.
Modern Healthcare reports on a provision for residency slots in the House version of the president's domestic policy package. Meanwhile, reports say health care employment has topped 16 million, the highest number since early in the pandemic.
In light of the pandemic’s shocking death toll among seniors, organizations are trying new strategies to help older Americans get better care.
KHN answers questions for seniors about how this new benefit might work.
More than 9 in 10 general acute-care hospitals have been penalized at least once in the past decade.
Democrats announced a deal on Tuesday for pared-back drug pricing measures as part of ongoing talks to secure intraparty support for massive spending bills. Under the compromise plan, Medicare Part D would be able to negotiate with drugmakers on the cost of some prescriptions.
A federal allocation plan meant to ensure equitable distribution of powerful monoclonal antibody treatments for high-risk patients fails to prioritize nursing home residents, a population that remains particularly vulnerable even after vaccination.
Health equity advocates see a once-in-a-generation opportunity to provide a dental benefit to millions of older Americans as Congress considers expanding Medicare services. But complicating that push is a debate over how many of the more than 60 million Medicare recipients should receive dental coverage.
The federal government’s hospital penalty program finishes its first decade by lowering payments to nearly half the nation’s hospitals for readmitting too many Medicare patients within a month. Penalties, though often small, are credited with helping reduce the number of patients returning for another Medicare stay within 30 days.
As lawmakers weigh new spending provisions to cover dental, hearing and vision services for Medicare beneficiaries, a group supporting Medicare Advantage plans is airing commercials that raise concerns about the funding for those private plans.
The ads for supplemental Medicare Advantage plans describe vision and dental benefits, even grocery discounts and food deliveries. But look at the fine print.
With an eye to shutting down Medicare drug price negotiations, drug companies and their lobbying groups gave roughly $1.6 million in the first six months of 2021, with Democrats edging closer than they have in a decade to Republicans’ total haul.
With booster doses of the Pfizer, Moderna and Johnson & Johnson covid vaccines accessible to millions of Americans, patients seek out guidance.
Following the devastating impact of covid-19 on nursing homes, state lawmakers want to be sure that government and private payments primarily go to improve care and staffing.
© 2026 KFF